Where is vancomycin derived from

Direct immunofluorescence is usually needed to confirm the diagnosis of LABD. Linear IgA deposition at the dermal—epidermal junction of the basement membrane zone is the characteristic finding of LABD. LABD can appear suddenly, appears to be idiosyncratic and unrelated to serum vancomycin levels 63 , Vancomycin is the most common cause of drug-induced LABD Other severe cutaneous syndromes including Stevens—Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, extensive fixed drug eruption, and leukocytoclastic vasculitis have all been described in association with vancomycin use 66 , Desensitization is contraindicated in patients with the DRESS syndrome and in those with exfoliative skin reactions such as Stevens—Johnson syndrome and toxic epidermal necrolysis.

Desensitization for IgE-mediated allergy is usually performed in an intensive care unit. Desensitization should be performed immediately before the required treatment, because maintaining tolerance requires continual exposure to the drug. A rapid desensitization protocol after up to date is shown in Table 1. Table 1. Rapid vancomycin desensitization protocole after up to date. Mild symptoms are managed interruption of infusion and treating the symptoms that do not subside spontaneously.

Once symptoms have subsided, the last tolerated step is repeated. If moderate or severe symptoms develop, the infusion should be discontinued and the symptoms treated. If vancomycin is discontinued, even for a short while, desensitization needs to be repeated in the previously described manner as the chances for anaphylaxis following the re-start of the vancomycin therapy are considerable Vancomycin has been a valuable agent for the management of infections caused by gram-positive bacteria for many decades.

In clinical trials, these compounds were compared to vancomycin and have been shown to be non-inferior 38 , 70 — This leads us to believe that vancomycin will continue to be used as the major glycopeptide antibiotic against MRSA and enterococci that are vancomycin susceptible, as long as agents with superior performance are not available.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Griffith RS. Introduction to vancomycin. Rev Infect Dis 3 Suppl :S—4. Moellering RC Jr. Vancomycin: a year reassessment.

Clin Infect Dis 42 Suppl 1 :S3—4. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Clin Infect Dis 52 3 :e18— Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin Microbiol Infect 19 12 —8. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 52 1 —7.

Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44 2 —6. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 38 1 :7— Oritavancin: mechanism of action. Clin Infect Dis 54 Suppl 3 :S—9. Brummett RE. Effects of antibiotic-diuretic interactions in the guinea pig model of ototoxicity.

Rev Infect Dis 3 Suppl :S— Retrospective study of the toxicity of preparations of vancomycin from to Antimicrob Agents Chemother 23 1 — Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 94 3 —6. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, Clin Infect Dis 36 4 — Hiramatsu K.

Vancomycin-resistant Staphylococcus aureus : a new model of antibiotic resistance. Lancet Infect Dis 1 3 — Reduced vancomycin susceptibility in Staphylococcus aureus , including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Clin Microbiol Rev 23 1 — Glycopeptide resistance in coagulase-negative Staphylococci. Strahilevitz J, Rubinstein E. Novel agents for resistant gram-positive infections — a review. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

J Clin Microbiol 42 6 — Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52 9 — Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus MRSA bacteraemia: the role of empiric antibiotic therapy.

Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect 19 11 — The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

Clin Infect Dis 54 6 — Interestingly, there was no difference in serum histamine levels between patients and control subjects, which could be explained only by the hypothesis that infection blunts the effect of glycopeptides. No matter how much toxicity is truly related to vancomycin, many researchers were convinced that problems could be avoided by careful monitoring of serum concentrations.

Measuring vancomycin levels in serum might be helpful to prevent toxicity and to assure an adequate therapeutic drug concentration. However, there are no definitive studies relating serum concentrations of vancomycin to treatment outcome. Indeed, the standard regimens of mg of vancomycin every 6 h or 1 g of vancomycin every 12 h appear to have been arbitrary.

However, many clinicians preferred to know whether the regimen they prescribed achieved an expected serum concentration, especially if dosage adjustments were necessitated by renal failure. Thus, to assure a desired concentration without actually measuring serum levels, several investigators constructed nomograms, several of which became popular [ 22 , 23 ].

Other investigators compared individualized dosing based on the actual serum concentration with dosing based on data from nomograms and found the individualized method to be superior [ 24 , 25 ]. However, by , without data to support either a therapeutic or a toxic range, Cantu et al.

With no clear consensus, many clinicians chose to dose according to nomogram data, whereas others measured serum concentrations in every case. Currently, the issue is being reconsidered, as will be discussed later in this article.

As noted above, shortly after being introduced, vancomycin was eclipsed by antibiotics that were considered to be less toxic and equally or more efficacious. Two events were primarily responsible for this dramatic resurgence. The first was the advent of pseudomembranous enterocolitis. Although Clostridium difficile is the primary agent of pseudomembranous enterocolitis, Staphylococcus aureus is clearly an occasional cause of the disorder [ 30 ].

Because vancomycin is active against both pathogens and is poorly absorbed from the intestinal tract, it became the drug of choice for treating pseudomembranous enterocolitis [ 31 ]. However, widespread vancomycin use, especially via the oral route, was responsible, at least in part, for the development of vancomycin-resistant enterococci VRE discussed below [ 32 ].

With the recent interest in intracolonic administration of vancomycin, VRE will likely remain a growing problem [ 33 , 34 ]. Reprinted from Kirst et al. The second event leading to increased vancomycin use was the widespread appearance of resistant pathogens: first, methicillin-resistant S. Known for decades as a cause of nosocomial infection [ 35 ], MRSA appeared suddenly in community isolates in Detroit and, later, throughout the world [ 36 , 37 ].

With its predictable activity against MRSA, vancomycin was the drug of choice, thus beginning a new era in the history of the antibiotic. In , Sorrell et al. Vancomycin was equally as effective against MRSA as standard therapy was against methicillin-susceptible S.

In addition, although patients had peak and trough vancomycin levels, which conformed to previously recommended ranges At the same time, my colleagues and I described 24 patients with infective endocarditis due to MRSA infection [ 40 ]. Most patients received other antibiotics in addition to vancomycin, so the mean duration of bacteremia 9.

One patient, the index case patient, remained bacteremic for 68 days without vancomycin therapy before undergoing tricuspid valve excision. Prior to surgery, she was given a variety of different regimens, and, each time, she appeared to respond initially. Therapy with vancomycin would have been started sooner, but the treating physician was reluctant to use it because of concerns about toxicity. For example, some patients with septic thrombophlebitis had persistent bacteremia, despite receiving treatment with heparin and vancomycin.

It was found that heparin causes vancomycin to precipitate when administered through the same tubing, leading to subtherapeutic concentrations of vancomycin [ 41 ]. Small and Chambers [ 42 ] studied S. In an effort to address the question of the efficacy of vancomycin, my colleagues and I studied patients with endocarditis due to MRSA. We planned to compare vancomycin monotherapy with combination therapy involving vancomycin plus either rifampin or gentamicin.

However, clinicians were reluctant to participate, fearing that the vancomycin-gentamicin combination would prove to be too toxic. Thus, the final study consisted of only 2 treatment arms: vancomycin monotherapy or vancomycin plus rifampin [ 43 ]. Vancomycin monotherapy resulted in prolonged bacteremia 9. Surprisingly, patients receiving vancomycin plus rifampin remained bacteremic longer than did those receiving vancomycin alone, although the data were not statistically significant.

In studies of coagulase-negative staphylococci, vancomycin and rifampin are usually synergistic in vitro [ 45 , 46 ]. The combination is less predictable against S. Whether antagonism played a role in our study is unknown. In a search for better alternatives, Markowitz et al. The emergence of penicillin-resistant S.

Vancomycin was well-established therapy for shunt-related meningitis, but there always was concern about its penetration across the blood-brain barrier. Because penicillin-resistant S. Studies show variable penetration in adults, but results are favorable if high doses of vancomycin are used. However, concomitant steroid therapy, which is also standard for acute meningitis in adults, may prevent adequate vancomycin levels in CSF. In pediatric patients, the combination of vancomycin plus steroids does not appear to be harmful [ 50 ].

With the accelerated use of vancomycin that began in the s, it was inevitable that resistance would occur.

VanD is also constitutive and has been found in only a few isolates [ 55 ]. Multiple genes are responsible for these different phenotypes, but they produce resistance by only one or the other of 2 common pathways. The target for vancomycin is the terminal D -alanyl- D -alanine of the growing peptidoglycan chain. These altered targets have reduced affinity for vancomycin, resulting in much higher MICs.

Depardieu et al. Using a strain of VanB-resistant Enterococcus faecalis , Aslangul et al. Later experiments with a VanB isolate proved that a 2-step mechanism is required for the development of resistance to the combination of teicoplanin and gentamicin [ 56 ]. VanE strains responded to high doses of glycopeptides, whereas standard doses led to treatment failure in the rabbit model of endocarditis.

Notably, because such strains may be indistinguishable from other types of resistant enterococci in clinical practice, Lafaurie et al. Finally, Lefort et al. Detection of such strains is important, because standard doses of vancomycin or teicoplanin might result in mutants with high-level glycopeptide resistance in infections with high bacterial density.

Perhaps the greatest concern about VRE is the potential for resistance to spread from enterococci to other pathogens, in particular to S.

Enterococci possess several systems, including plasmids and transposons, that enable the transfer of genetic material to other bacteria. Although the transfer of resistance from enterococci to S.

Intermediate resistance to vancomycin had already been reported among staphylococci, but it was not caused by transfer of genetic material from enterococci. The first staphylococci with reduced susceptibility to vancomycin were reported from Japan in [ 60 , 61 ]. Additional strains soon appeared in the United States. It has only been within the last several years that vancomycin-intermediate.

This bug has overcome an otherwise steadfast drug. Many inpatient settings now focus on optimizing vancomycin dosing and monitoring to preserve its integrity to fight serious MRSA infections. Does achieving target troughs affect clinical outcomes and does more aggressive vancomycin dosing induce toxicities? Dosing and drug monitoring for vancomycin is considered an art for many pharmacists.

Dosing strategies were first established with the development of vancomycin. Pharmacodynamic studies against the bacterial pathogens have been limited to in vitro or animal models. The evidenced-based data in this area remains very thin.

Steady state is reached approximately after the third or forth dose of vancomycin. Therefore, levels should be obtained at that point of therapy. Vancomycin is considered a concentration-independent time dependent killer for staphylococci and streptococci, making intermittent IV infusions the preferred method of administration.

Several smaller studies have evaluated if continuous infusion versus standard Q8 or Q12 hour dosing affect outcomes. The evaluated data do not suggest that continuous infusion has a significant impact. Dose adjustment in renal impaired patients is necessary. These dosing adjustments were established early on and have continued to be adjusted with the emergence of published data. So, what is the best possible monitoring parameter? What is the optimal target serum trough level?

Research to develop alternatives to vancomycin has been in progress for more than 20 years. Nonetheless, vancomycin is as important as ever because it is used to treat the urgent threat of Clostridium difficile colitis and the serious threat of Staphylococcus aureus infections.

For more on bacterial resistance to antibiotics, see the update on tetracycline. Tetracycline , the widely used broad-spectrum antibiotic, was the Molecule of the Week for March 4, Enzalutamide , the Molecule of the Week for July 28, , is a drug for treating refractory metastatic prostate cancer that has a convoluted history of lawsuits and changing ownerships.

In the most recent episode, Pfizer outbid several competitors to acquire Medivation , a company that currently markets enzalutamide under the trade name Xtandi. Learn more about this molecule from CAS , the most authoritative and comprehensive source for chemical information. If your favorite molecule is not in our archive , please send an email to motw acs. The molecule can be notable for its current or historical importance or for any quirky reason.